Guggenheim lowered the firm’s price target on Bruker (BRKR) to $50 from $58 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies in its diagnostics and life science tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- PTAB upholds Seer patent for nano- and microparticles in challenge by Bruker
- Rising helium prices could create headwind for Bruker, says Jefferies
- Bruker Announces Board Changes and Declares Quarterly Dividend
- Bruker’s 2025 Earnings Call Maps a Cautious Recovery
- Bruker price target lowered to $49 from $60 at BofA